King Pharmaceuticals Articles
King 2003 revenues up 35%, but earnings slip
1 March 2004
COO and head of planning appointed at King Pharma
9 February 2004
Elan to dispose of European sales and marketing units?
15 December 2003
Stock Commentary - New York
10 November 2003
King reins in 2003 profit forecasts
10 November 2003
King's Intal HFA on track for US approval
10 November 2003
FDA clears Novavax' estrogen therapy
20 October 2003
Aderis in $75M US public offering
8 September 2003
Elan shareholders approve sale to King
30 June 2003
King receives approval of sNDA for AtroPen
30 June 2003
King completes Elan acquisition at discount
23 June 2003
SkyePharma to work on Altace follow-up
26 May 2003
Lost revenues hit Elan as losses widen further
12 May 2003
King gets Orange Book patent for Levoxyl
5 May 2003
Stock Commentary - New York
28 April 2003
Stock Commentary - New York
14 April 2003
King set to pull plug on $850M Elan deal
7 April 2003
Elan in $10M accord with Ingenium Pharma
31 March 2003
Elan shareholders OK "critical" divestment
31 March 2003
Stock Commentary - New York
24 March 2003
King Pharma earnings hit by exceptionals
24 February 2003
Novavax completes $16.6M financing
24 February 2003
Pharma set to see
17 February 2003
King Pharma revises forecasts after Elan unit acquisitions
10 February 2003
Stock Commentary week to Jan 13 - New York
20 January 2003
Shareholders OK King/Meridian merger
13 January 2003
Shire hit by Adderall XR patent challenge
13 January 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
King buys Aventis drug rights for $200M
6 January 2003
King Pharma posts 36% leap in earnings
5 August 2002
King 2003 guidance predicts EPS of $1.66
8 July 2002
King Pharma predicts EPS of $1.66 in 2003
8 July 2002
Novavax gets $10M from King Pharma
8 July 2002
Stock Commentary - New York
1 July 2002
King Pharma has 20 Levoxyl patents pending
1 July 2002
Stock Commentary - New York
20 May 2002
King to buy Ortho-Prefest for $108 million
13 May 2002
Novavax withdraws Estrasorb file in USA
6 May 2002
King Pharma launches Altace DTC campaign
8 April 2002
King denies directors directly sold stock
25 February 2002
King Pharma says share price slump unjustified
11 February 2002
King Pharm sets tender offer pricing
11 December 2001
King files for injectable HRT in USA
1 November 2001
King promotes president to CEO
25 October 2001
King hires cardiovascular sales force
5 October 2001
King pays $285 million for B-MS drugs
10 August 2001
King Pharmaceuticals 2nd-qtr earnings leap 77%
25 July 2001
FDA orders cutback on Synthroid distribution
16 July 2001
Novavax files for Estrasorb approval in USA
3 July 2001
FDA approves King's Levoxyl
30 May 2001
King Pharma profits more than double, driven by Altace
21 February 2001
HOPE sub-study backs up ramipril benefit
20 February 2001
King not looking to buy C-W pharma unit
15 January 2001
Avandia to be tested in diabetes prevention
9 November 2000
King gets $50 million from AHP for Altace
10 October 2000
On the move at King Pharma
14 September 2000
Shareholders approve merger of King Pharmaceuticals and Jones Pharma
4 September 2000
King's turnover tops $100 million
25 July 2000
Stock Commentary New York
13 July 2000
King Pharma starts NYSE trading
25 May 2000
King Pharma to list on New York SE
10 May 2000
King Pharma raises $165.5 million
20 April 2000
King Pharma deal for Menest in Lat America
17 March 2000
Appointment at King Pharmaceuticals
16 March 2000
Favorable ruling for King/Medco merger
1 March 2000
King seeks new indications for Altace
20 January 2000
King Pharmaceuticals acquires Medco Research
2 December 1999
King Pharmaceutical confident about its prospects
4 November 1999
Eli Lilly signs glucagon deal with E-Z-EM
24 August 1999
King acquires certain rights to Lilly's Lorabid
5 August 1999
King Pharma expects to exceed expectations
6 July 1999
King and Falcon sign Cortisporin deal
18 June 1999
HMR sells brands to King Pharma
24 December 1998
Monarch Pharma Acquires Two Products From Roberts
28 October 1996
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
